PriceTargets.com logo

Rhythm Pharmaceuticals - RYTM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $62.30
  • Forecasted Upside: 4.95%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$59.36 As of 11/20/2024 01:00 AM ET
▼ -0.61 (-1.02%)

This chart shows the closing price for RYTM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rhythm Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RYTM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RYTM

Analyst Price Target is $62.30
▲ +4.95% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is $62.30, with a high forecast of $80.00 and a low forecast of $52.00. The average price target represents a 4.95% upside from the last price of $59.36.

This chart shows the closing price for RYTM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 contributing investment analysts is to moderate buy stock in Rhythm Pharmaceuticals. This rating has held steady since April 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
11/7/2024HC WainwrightBoost TargetBuy ➝ Buy$64.00 ➝ $69.00
11/6/2024TD CowenBoost TargetBuy ➝ Buy$55.00 ➝ $65.00
11/6/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$77.00 ➝ $80.00
11/6/2024Needham & Company LLCBoost TargetBuy ➝ Buy$55.00 ➝ $64.00
10/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
10/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$64.00 ➝ $64.00
10/21/2024GuggenheimInitiated CoverageBuy$70.00
10/14/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$48.00 ➝ $52.00
10/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$64.00 ➝ $64.00
9/18/2024HC WainwrightInitiated CoverageBuy$64.00
9/17/2024JMP SecuritiesInitiated CoverageOutperform$64.00
8/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
7/25/2024Needham & Company LLCBoost TargetBuy ➝ Buy$46.00 ➝ $55.00
5/8/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$80.00 ➝ $79.00
5/8/2024Bank of AmericaDowngradeBuy ➝ Neutral$49.00 ➝ $42.00
5/7/2024Needham & Company LLCLower TargetBuy ➝ Buy$50.00 ➝ $46.00
4/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00
4/18/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$53.00 ➝ $52.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00
2/22/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00
1/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00
1/25/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$42.00 ➝ $52.00
1/4/2024Needham & Company LLCBoost TargetBuy ➝ Buy$45.00 ➝ $50.00
12/19/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$48.00 ➝ $53.00
12/19/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$29.00 ➝ $55.00
12/7/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$38.00 ➝ $42.00
12/7/2023Needham & Company LLCBoost TargetBuy ➝ Buy$32.00 ➝ $45.00
11/8/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$38.00 ➝ $40.00
10/10/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
8/2/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$32.00
8/2/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$28.00
8/1/2023Bank of AmericaUpgradeNeutral ➝ Buy$22.00 ➝ $27.00
3/2/2023Canaccord Genuity GroupBoost TargetBuy$52.00 ➝ $56.00
3/2/2023Morgan StanleyBoost TargetEqual Weight$26.00 ➝ $28.00
3/2/2023The Goldman Sachs GroupBoost TargetBuy$40.00 ➝ $45.00
3/2/2023Needham & Company LLCReiterated RatingBuy$32.00
3/2/2023LADENBURG THALM/SH SHReiterated RatingBuy$35.00
1/26/2023The Goldman Sachs GroupBoost TargetBuy$35.00 ➝ $40.00
1/18/2023Canaccord Genuity GroupReiterated RatingBuy
11/10/2022The Goldman Sachs GroupBoost TargetBuy$31.00 ➝ $35.00
11/9/2022Morgan StanleyBoost TargetEqual Weight$16.00 ➝ $26.00
9/8/2022The Goldman Sachs GroupBoost TargetBuy$28.00 ➝ $31.00
8/7/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$28.00
8/5/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$8.00 ➝ $20.00
8/3/2022Morgan StanleyBoost TargetEqual Weight$8.00 ➝ $16.00
8/2/2022Wells Fargo & CompanyBoost Target$22.00 ➝ $35.00
7/20/2022Stifel NicolausBoost Target$25.00 ➝ $37.00
7/15/2022Morgan StanleyBoost TargetEqual Weight$4.00 ➝ $8.00
7/13/2022LADENBURG THALM/SH SHBoost Target$15.00 ➝ $23.00
7/12/2022The Goldman Sachs GroupBoost TargetNeutral$4.00 ➝ $6.00
6/17/2022Needham & Company LLCLower TargetBuy$40.00 ➝ $25.00
6/17/2022Stifel NicolausBoost Target$23.00 ➝ $25.00
6/7/2022Morgan StanleyLower TargetEqual Weight$12.00 ➝ $4.00
5/24/2022The Goldman Sachs GroupLower TargetNeutral$8.00 ➝ $7.00
4/7/2022The Goldman Sachs GroupLower TargetNeutral$10.00 ➝ $9.00
3/7/2022Canaccord Genuity GroupLower Target$45.00 ➝ $36.00
3/2/2022Stifel NicolausInitiated CoverageBuy
2/25/2022Needham & Company LLCLower TargetBuy$50.00 ➝ $45.00
2/17/2022Needham & Company LLCReiterated RatingBuy$50.00
2/17/2022LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$15.00
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$30.00
11/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$50.00 ➝ $15.00
9/14/2021The Goldman Sachs GroupUpgradeHold$14.00
8/4/2021Morgan StanleyLower TargetOverweight$57.00 ➝ $54.00
8/4/2021LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
8/4/2021Bank of AmericaDowngradeNeutral ➝ Underperform$33.00 ➝ $17.00
2/25/2021Morgan StanleyBoost TargetOverweight$53.00 ➝ $57.00
2/18/2021Morgan StanleyBoost TargetPositive ➝ Overweight$33.00 ➝ $53.00
1/27/2021Stifel NicolausBoost TargetPositive ➝ Buy$36.00 ➝ $67.00
1/27/2021LADENBURG THALM/SH SHBoost TargetPositive ➝ Buy$43.00 ➝ $60.00
1/5/2021Stifel NicolausReiterated RatingTop Pick
11/30/2020Morgan StanleyBoost TargetOverweight$30.00 ➝ $33.00
11/30/2020Bank of AmericaDowngradeBuy ➝ Neutral$27.00 ➝ $33.00
11/3/2020Morgan StanleyLower TargetOverweight$31.00 ➝ $30.00
10/26/2020Stifel NicolausBoost TargetPositive ➝ Buy$31.00 ➝ $36.00
8/3/2020Needham & Company LLCInitiated CoverageBuy$42.00
8/3/2020Stifel NicolausReiterated RatingBuy$31.00
7/16/2020LADENBURG THALM/SH SHReiterated RatingBuy$43.00
6/24/2020Needham & Company LLCInitiated CoverageBuy$42.00
5/4/2020Stifel NicolausReiterated RatingBuy$31.00
5/4/2020Needham & Company LLCReiterated RatingBuy$42.00
4/15/2020Morgan StanleyLower TargetOverweight$33.00 ➝ $31.00
3/31/2020LADENBURG THALM/SH SHReiterated RatingBuy$43.00
3/2/2020Stifel NicolausReiterated RatingBuy$34.00
1/8/2020The Goldman Sachs GroupInitiated CoverageSell$18.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 11 very positive mentions
  • 22 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 10 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/23/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 17 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/22/2024
  • 13 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/21/2024
  • 13 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 14 very positive mentions
  • 34 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 14 very positive mentions
  • 34 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $59.36
Low: $58.05
High: $60.79

50 Day Range

MA: $52.74
Low: $47.20
High: $67.33

52 Week Range

Now: $59.36
Low: $31.52
High: $68.58

Volume

388,321 shs

Average Volume

549,000 shs

Market Capitalization

$3.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Rhythm Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Rhythm Pharmaceuticals in the last twelve months: Bank of America Co., Canaccord Genuity Group Inc., Guggenheim, HC Wainwright, JMP Securities, Morgan Stanley, Needham & Company LLC, TD Cowen, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for RYTM.

What is the current price target for Rhythm Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Rhythm Pharmaceuticals in the last year. Their average twelve-month price target is $62.30, suggesting a possible upside of 5.0%. Canaccord Genuity Group Inc. has the highest price target set, predicting RYTM will reach $80.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $52.00 for Rhythm Pharmaceuticals in the next year.
View the latest price targets for RYTM.

What is the current consensus analyst rating for Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RYTM.

What other companies compete with Rhythm Pharmaceuticals?

Other companies that are similar to Rhythm Pharmaceuticals include Morphic, Arvinas, Pliant Therapeutics, Annexon and Theravance Biopharma. Learn More about companies similar to Rhythm Pharmaceuticals.

How do I contact Rhythm Pharmaceuticals' investor relations team?

Rhythm Pharmaceuticals' physical mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company's listed phone number is (857) 264-4280 and its investor relations email address is [email protected]. The official website for Rhythm Pharmaceuticals is www.rhythmtx.com. Learn More about contacing Rhythm Pharmaceuticals investor relations.